Tuberculosis cost-effectiveness of therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Changes made per Mahshid's request)
Line 40: Line 40:


[[Category:Disease]]
[[Category:Disease]]
[[Category:Infectious disease]]
 
[[Category:Pulmonology]]
[[Category:Pulmonology]]
[[Category:Primary care]]
[[Category:Primary care]]

Revision as of 19:02, 18 September 2017

Tuberculosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tuberculosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Children

HIV Coinfection

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Special Conditions
Drug-resistant

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tuberculosis cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tuberculosis cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tuberculosis cost-effectiveness of therapy

CDC on Tuberculosis cost-effectiveness of therapy

Tuberculosis cost-effectiveness of therapy in the news

Blogs on Tuberculosis cost-effectiveness of therapy

Directions to Hospitals Treating Tuberculosis

Risk calculators and risk factors for Tuberculosis cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Treatment of tuberculosis must be analysed for relative cost effectiveness of inpatient and outpatient models of care as it will benefit regions where tuberculosis is highly prevalent. Unless there is severe complications it is highly recommended to treat the TB patient in ambulatory care rather than inpatient services.[1]

Cost effectiveness of therapy

While measurements of morbidity and mortality are key considerations for estimating the burden of disease in populations, they provide an incomplete picture of the adverse impact of ill health on human welfare. In particular, the economic consequences of poor health can be substantial.

Analysis of the economic impact of ill-health addresses a number of policy questions concerning the consequences of disease or injury. Some of these questions relate to the microeconomic level of households, firms or government – such as the impact of ill-health on a household’s income or a firm’s profits – while others relate to the macroeconomic level, including the aggregate impact of a disease on a country’s current and future gross domestic product (GDP).

WHO proposes a defined conceptual framework within which the economic impact of diseases and injuries can be considered and appropriately estimated. [2]

The current regimen costs about US$ 4000 per patient, exclusive of laboratory, human resource and patient opportunity costs. [3]


The cost effectiveness in various tubercular control interventions in Africa region is give below. [3]

Intervention Yearly costs with 95% coverage level
Minimal DOTS 366.3 million $
Full DOTS 612.2 million $
Minimal DOTS with resistant cases 495.9 million $
Full combination 739.4 million $

References

  1. Fitzpatrick C, Floyd K (2012). "A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis". Pharmacoeconomics. 30 (1): 63–80. doi:10.2165/11595340-000000000-00000. PMID 22070215.
  2. "Cost effectiveness and strategic planning".
  3. 3.0 3.1 "Cost effectiveness purposed by WHO".

Template:WH Template:WS